Overview
- HER2 (Human Epidermal Growth Factor Receptor 2) is a receptor tyrosine kinase overexpressed in approximately 15-20% of breast cancers and other tumors (e.g., gastric cancer).
- HER2 overexpression leads to increased cell proliferation and survival, associated with aggressive tumor behavior.
- HER2-targeted therapies specifically inhibit HER2 signaling, improving outcomes in HER2-positive cancers.
Common HER2-Targeted Agents
| Drug Name | Class | Mechanism of Action | Indications |
|---|---|---|---|
| Trastuzumab (Herceptin®) | Monoclonal antibody | Binds HER2 extracellular domain → inhibits signaling & flags cells for immune-mediated destruction | HER2+ breast, gastric/gastroesophageal cancer |
| Pertuzumab (Perjeta®) | Monoclonal antibody | Binds different HER2 domain → blocks HER2 dimerization | HER2+ breast cancer (in combination) |
| Ado-trastuzumab emtansine (T-DM1, Kadcyla®) | Antibody-drug conjugate | Trastuzumab linked to DM1 cytotoxic agent; delivers chemo to HER2+ cells | HER2+ metastatic breast cancer post trastuzumab/ taxanes |
| Fam-trastuzumab deruxtecan (Enhertu®) | Antibody-drug conjugate | Trastuzumab linked to topoisomerase I inhibitor payload | HER2+ metastatic breast and gastric cancer |
| Lapatinib (Tykerb®) | Small molecule TKI | Inhibits intracellular tyrosine kinase domains of HER2 and EGFR | HER2+ breast cancer (advanced) |
| Neratinib (Nerlynx®) | Small molecule TKI | Irreversible pan-HER TKI | Extended adjuvant treatment of HER2+ breast cancer |
| Tucatinib (Tukysa®) | Small molecule TKI | Selective HER2 TKI | HER2+ metastatic breast cancer (with trastuzumab and capecitabine) |
Pharmacology Highlights
- Monoclonal antibodies: IV administration, long half-life, immune-mediated mechanisms.
- TKIs: Oral administration, inhibit kinase activity intracellularly, often used in combination with chemotherapy or antibodies.
- Antibody-drug conjugates (ADCs): Targeted delivery of cytotoxic agents, balancing efficacy and toxicity.
Common Toxicities
| Agent | Key Toxicities | Management/Monitoring |
|---|---|---|
| Trastuzumab | Cardiotoxicity (decreased LVEF), infusion reactions | Baseline & periodic echocardiograms, monitor symptoms |
| Pertuzumab | Similar to trastuzumab; diarrhea, rash | Supportive care, hydration |
| ADCs (T-DM1, Deruxtecan) | Thrombocytopenia, hepatotoxicity, interstitial lung disease (ILD) | CBC monitoring, LFTs, pulmonary symptoms monitoring |
| TKIs (Lapatinib, Neratinib) | Diarrhea (severe), rash, hepatotoxicity | Prophylactic antidiarrheals, skin care, LFTs |
| Tucatinib | Diarrhea, hepatotoxicity | Supportive care, liver function monitoring |
Clinical Considerations
- HER2 testing (IHC, FISH) is essential for patient selection.
- Cardiac monitoring is critical with trastuzumab-based therapies.
- Diarrhea prophylaxis and management important with TKIs.
- ADCs require vigilance for pulmonary toxicity.
- Combination regimens (e.g., trastuzumab + pertuzumab + chemo) improve outcomes but increase toxicity risk.
Practice Pearls
- Early detection of cardiotoxicity enables treatment interruption and recovery.
- Patient education on diarrhea management improves adherence.
- Familiarity with administration schedules and infusion reactions helps optimize patient care.
- Newer agents (e.g., trastuzumab deruxtecan) show promise but require close toxicity monitoring.
Key Takeaway:
HER2-targeted therapies have revolutionized treatment of HER2-positive cancers, markedly improving survival. Safe and effective use requires careful patient selection, toxicity monitoring, and supportive care.